Adicet Bio (ACET)
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in t...
- Open
- 9.000
- High
- 9.180
- Low
- 8.841
- Prev. Close
- 8.950
- Volume
- 261.59K
- Turnover
- 2.47M
- Avg Price
- 9.432
- Bid/Ask Ratio
- --
- Amplitude
- 3.79%
- 52wk High
- 17.438
- Volume Ratio
- 2.65
- Turnover Ratio
- 4.63%
Adicet Bio Analyst Rating
View moreForecast & Rating
Aug 26, 2026Price forecast
$33.17268.11%
Forecast & RatingStrong buy
6analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 7 hours ago
Adicet Bio wins FDA IND clearance for ADI-212 prostate cancer trial
- Market Beat · Aug 24 at 09:14 AM
Adicet Bio, Inc. (NASDAQ:ACET) Given Consensus Rating of "Moderate Buy" by Analysts
- Market Beat · Aug 11 at 11:04 AM
Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy
- PUBT · Aug 5 at 04:23 PM
Adicet Bio Q2 FY26 net loss widens to $21.4 million; cash and short-term investments total $118.2 million
- Market Beat · Jul 30 at 03:41 AM
Adicet Bio (ACET) Projected to Release Quarterly Earnings on Thursday
- benzinga_article · Jun 25 at 07:05 AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
